China pet food sector Report Interpretation

Overview

UBS's Q226 preview for China's pet-food sector argues that demand remains healthy, but earnings recovery will lag revenue growth as companies spend heavily to defend or gain share and face FX-related losses. The report favors CPF for domestic growth and potential overseas capacity expansion, while remaining Neutral on Gambol and Petpal because of margin pressure.

Core views

China's pet-food market continued to grow resiliently in H126 despite a difficult macro backdrop. UBS cites Meritco data showing year-to-date online GMV up at a high-single-digit YoY rate, supported by stable pet ownership and continuing premiumization demand. However, the report identifies profitability—not demand—as the sector's central issue: more intense competition across major online channels is lifting promotional spending and customer-acquisition costs, while renminbi appreciation is increasing FX losses for export-oriented companies. UBS therefore expects broadly positive revenue growth among listed companies but weaker margins and profits. For Gambol, UBS forecasts owned-brand sales growth of 10-20% YoY in Q226, with OEM/ODM revenue broadly flat. This would produce high-single-digit to mid-teens company revenue growth, but net profit is expected to decline by more than 20% YoY because of higher FX losses and elevated selling expenses amid tougher competition. CPF is expected to show the strongest revenue trajectory. UBS forecasts Q226 domestic sales growth of roughly 40-50% YoY and overseas sales growth of 10% YoY, implying company revenue growth of about 20-25%. Nevertheless, the report expects net profit to decline by more than 20% YoY as selling expenses rise and FX losses weigh. UBS maintains its Buy rating because strong domestic sales momentum and a potential overseas-capacity ramp-up in H226 could support the company. For Petpal, UBS expects low-single-digit Q226 revenue growth: domestic sales should rise 15-20% YoY while overseas sales remain broadly flat. Net profit is forecast to fall around 30-40% YoY, reflecting heightened selling expenses and FX losses. The report notes that overseas revenue represented about 80% of Petpal's 2025 sales, making its earnings relatively exposed to currency movements. UBS also discusses the recent “thousand-cat paralysis” controversy, following reports and online discussion that some affected cats had consumed Fregate, a Gambol brand, or Pure & Natural cat food products. No official causal conclusion has been reached. UBS considers it too early to quantify any financial impact, but expects the issue to weigh on sentiment and create near-term uncertainty around purchasing behavior for the brands involved. It will monitor developments, consumer feedback, and potential regulatory or investigative updates. Overall, UBS expects leading players to continue prioritizing market-share gains through brand investment and promotions, so earnings recovery is likely to trail revenue growth. It maintains Buy on CPF, while keeping Neutral ratings on Gambol and Petpal amid persistent margin pressure and an increasingly competitive environment.

Analysis framework

UBS begins with sector demand indicators and then assesses how competition, selling costs and currency movements translate revenue growth into weaker profitability. It applies these drivers to Q226 sales and earnings expectations for Gambol, CPF and Petpal, considers the potential consumer and sentiment effects of the product-safety controversy, and values the three companies using DCF.

Methodology notes

• Industry AnalysisSupply-demand framework

  Sector demand and competitive intensity analysis

  UBS contrasts resilient demand, reflected in online GMV and premiumization, with intensifying online competition and higher promotional spending to explain why earnings may lag revenue growth.

• Valuation methodsDCF (Discounted Cash Flow)

  DCF methodology

  UBS states that it bases valuation for Gambol, CPF and Petpal on discounted cash flow methodology.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Yantai China Pet Foods (002891.SZ)

  UBS maintains Buy, citing strong domestic sales momentum and potential overseas capacity ramp-up in H226.

  Strengths

  Domestic sales are expected to grow around 40-50% YoY in Q226; overseas sales are expected to grow 10% YoY.

  Weaknesses

  Net profit is expected to decline by more than 20% YoY because of higher selling expenses and FX losses.

  Comparison

  UBS expects stronger top-line momentum than at Gambol and Petpal.

  Risks

  Competition-driven spending, FX losses and slower-than-expected domestic-market development.

• Gambol Pet Group (301498.SZ)

  UBS maintains a Neutral rating amid margin pressure and increased competitive intensity.

  Strengths

  Owned-brand sales are expected to grow 10-20% YoY in Q226.

  Weaknesses

  OEM/ODM revenue is expected to be broadly flat and net profit to decline by more than 20% YoY.

  Comparison

  Revenue is expected to grow at a high-single-digit to mid-teens pace, below CPF's projected growth.

  Risks

  FX losses, elevated selling expenses, competitive pressure and uncertainty linked to the Fregate controversy.

• Petpal Pet Nutrition Technology (300673.SZ)

  UBS maintains a Neutral rating because profitability remains under pressure.

  Strengths

  Domestic sales are expected to grow 15-20% YoY in Q226.

  Weaknesses

  Overall revenue is expected to grow only at a low-single-digit rate and net profit to decline around 30-40% YoY.

  Comparison

  Its overseas sales are expected to be broadly flat, versus CPF's projected 10% overseas growth.

  Risks

  High overseas exposure, FX losses and rising selling expenses amid fierce competition.

Key data

• China pet-food online GMVHigh-single-digit YoY growth in H126 YTDAccording to Meritco; UBS cites resilient demand despite the macro backdrop.
• Gambol owned-brand sales growth10-20% YoY in Q226OEM/ODM revenue is expected to remain broadly flat.
• Gambol net profitDecline of more than 20% YoY in Q226Expected to reflect higher FX losses and selling expenses.
• CPF domestic sales growthAround 40-50% YoY in Q226Overseas sales are expected to grow 10% YoY.
• CPF revenue growthApproximately 20-25% YoY in Q226Despite strong top-line momentum, net profit is expected to decline by more than 20% YoY.
• Petpal net profitDecline of around 30-40% YoY in Q226Driven by competition-related selling expenses and FX losses.
• Petpal overseas revenue exposurec.80% of 2025 salesThis increases relative exposure to FX movements.

Impact & implications

The report's central implication is that healthy category demand alone is unlikely to produce near-term earnings recovery while companies pursue share through promotions and brand investment. UBS sees CPF as comparatively supported by domestic momentum and possible overseas capacity expansion, whereas Gambol and Petpal face continuing profitability pressure.

Risks

• Domestic brands may expand more slowly than expected.
• Pet-food safety issues could harm the sector or affected brands.
• More severe price competition could further weaken profitability.
• Sharp increases in chicken or grain prices could raise costs.
• Further renminbi appreciation against the US dollar could widen FX losses.
• US-market exposure leaves companies vulnerable to tariff effects.

What to watch

• Developments, consumer feedback, and any regulatory or investigative updates related to the “thousand-cat paralysis” controversy.
• Whether domestic-brand growth and market-share investment translate into sustainable earnings contribution.
• The pace of CPF's overseas-capacity ramp-up in H226.
• Promotional intensity, selling expenses and renminbi movements affecting FX losses.